Northway Biotech, a renowned CDMO specializing in protein-based biologics and gene therapies, has joined forces with Diorasis Therapeutics to advance AAV gene therapy for the treatment of glaucoma. Leveraging Northway Biotech’s extensive experience in cell line development, process optimization, and cGMP manufacturing, the partnership aims to establish a scalable production process for DTx’s lead gene therapy candidate.
This collaboration encompasses AAV process development, analytical method development, pre-clinical and clinical manufacturing, and viral clearance studies to ensure the quality and safety of the therapy. With a focus on delivering long-lasting efficacy from a single dose, Diorasis Therapeutics is dedicated to transforming glaucoma care by addressing the root cause of elevated intraocular pressure. Supported by Northway Biotech’s commitment to high-quality execution and innovation, this partnership marks a significant milestone in advancing gene therapy for ophthalmic diseases.
Read more on palmbeachpost.com